A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.

开始日期2026-07-07

申办/合作机构

Washington University School of Medicine

[+2]

NCT07628062

/ Not yet recruiting临床2期

Open-Label, Single-Arm Phase 2 Study Of Nogapendekin Alfa Inbakicept, PD-L1 T-HaNK, And Bevacizumab And Randomized Phase 2B Study Of Nogapendekin Alfa Inbakicept, Bevacizumab, And Tumor Treatment Fields With Or Without PD-L1 T-HaNK In Participants With Recurrent Or Progressive Glioblastoma

This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The study includes a Phase 2a safety lead-in followed by a randomized Phase 2 comparison of a de-intensified experimental chemoradiation approach versus standard-of-care chemoradiation.

开始日期2026-07-22

申办/合作机构

ImmunityBio, Inc.

NCT07686380

/ Not yet recruiting临床2期IIT

Phase II Trial of IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

Background:
Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year. Researchers want to know if a drug (N-803) alone or combined with a vaccine (ETBX-071) can reduce PSA in BCR prostate cancer after radiation.
Objective:
To test a study drug alone and combined with a vaccine in people with BCR prostate cancer who have been treated with targeted radiation to areas of recurrent prostate cancer in the past.
Eligibility:
People aged 18 years and older with BCR prostate cancer who have previously undergone treatment with stereotactic body radiation therapy (SBRT).
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have tests of their heart and kidney function. They will have 3 different imaging scans of their tumors.
N-803 is injected under the skin of the abdomen. ETBX-071 is injected under the skin of thigh.
Participants will be divided into 2 groups: 1 group will get N-803 alone; 1 group will get both N-803 and ETBX-071.
The drug or drugs will be given on the first day of 21-day treatment cycles. Participants will have 8 treatment cycles.
Participants will have a follow-up visit 3 weeks after their last dose of the study drugs. Blood tests and all 3 imaging scans will be repeated.
Follow-up visits will continue every 4 to 8 weeks for 5 years. These visits will include a positron emission tomography (PET) scan every 6 months.

开始日期2026-07-14

申办/合作机构

National Cancer Institute

100 项与诺格白介素α-因奇西普相关的临床结果

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的转化医学

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的专利（医药）

登录后查看更多信息

390

项与诺格白介素α-因奇西普相关的文献（医药）

2026-12-31·Emerging Microbes & Infections

Neuraminidase-inhibiting antibodies boosted by H1N1pdm infection cross-react differently with H5N1 of clades 2.3.4.4b and 2.3.2.1a

Article

作者: Aziz, Dinah Binte ; Tan, Yee-Joo ; Chan, Yee Teng ; Liew, Kong Yen ; Tambyah, Paul ; Tan, Chee Wah

Antibodies against neuraminidase (NA) are an independent correlate of protection and the antigenic relatedness between H1N1pdm and H5N1 NAs suggests that seasonal influenza infection may provide cross-reactive immunity. In this study, recent H1N1pdm infection elicited modest NA-inhibiting (NAI) antibody responses against contemporary A/Victoria/4897/2022 (H1N1pdm) but strong responses against older A/California/7/2009 (H1N1pdm). Convalescent sera exhibited significantly higher cross-reactive NAI against clade 2.3.4.4b H5N1 (A/Texas/37/2024) than non-flu A patients, whereas H3N2 infection did not elicit such cross-reactivity. NAI titres were comparable between N1-California and N1-Texas but lower against N1-Victoria, indicating greater antigenic similarity between N1-California and N1-Texas. This was supported by stronger inhibition of N1-Texas by N1-California sheep antiserum compared with N1-Victoria sheep antiserum. Surprisingly, H1N1pdm-infected patients exhibited very low NAI against clade 2.3.2.1a H5N1 (N1-Bangladesh; GMT of 171 vs GMT 1159 for N1-Texas). Mouse antisera demonstrated reduced reciprocal inhibition between N1-Texas and N1-Bangladesh, consistent with their antigenic divergence. When four residues in N1-Bangladesh were substituted with their corresponding residues in N1-Texas, N1-Bangladesh antiserum showed reduced NAI, while N1-Texas antisera showed increased inhibition compared with wild-type N1-Bangladesh. This suggests that these amino acid differences are partially responsible for their antigenic divergence. Importantly, longitudinal analysis revealed that boosted cross-reactive NAI responses waned by day 90 post-infection, highlighting their limited durability. Together, these findings demonstrate that seasonal H1N1pdm infection can transiently boost cross-reactive NAI antibodies against clade 2.3.4.4b H5N1, but antigenic divergence in clade 2.3.2.1a limits cross-reactivity. As such, the impact of pre-existing antibody during an H5N1 outbreak is dependent on the infecting clade.

2026-06-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Advances in intravesical therapy for non-muscle-invasive bladder cancer

Review

作者: Tang, Yanfeng ; Zeng, Hao ; Zhu, Qiyu ; Xu, Chenhao ; Chen, Junru ; Liu, Haoyang ; Wang, Ling

Non-muscle-invasive bladder cancer (NMIBC) accounts for roughly 75% of newly diagnosed bladder cancer and associates with high risk of recurrence and progression. Intravesical therapy remains the cornerstone of NMIBC management following transurethral resection of bladder tumor (TURBT). For low-risk NMIBC, immediate single instillation of chemotherapy after TURBT effectively reduces recurrence. Intermediate-risk patients could benefit from either intravesical chemotherapy or Bacillus Calmette-Guérin (BCG) instillation, with emerging therapies such as UGN-102 chemoablation showing promise. For high/very high-risk NMIBC, full-dose, 3-year BCG instillation remains the standard of care, However, global BCG shortages and treatment failures have prompted the need for alternative strategies. Optimization of BCG regimens, such as two induction courses, may preserve efficacy while improving feasibility. Moreover, alternative agents such as sequential gemcitabine and docetaxel instillation have demonstrated favorable outcomes in both BCG-naïve and BCG-unresponsive patients. For those with BCG failure, a number of novel therapies are under active investigation. Gene therapy (nadofaragene firadenovec), oncolytic viral therapy (CG0070), interleukin-15 superagonist (Nogapendekin alfa-inbakicept), and innovative drug delivery systems (TAR-200) have shown encouraging clinical potential in this population. This review provides an overview of current intravesical treatment strategies for NMIBC across different risk groups and highlights promising new approaches aimed at overcoming the limitations of BCG therapy.

2026-05-01·Biomaterials advances

A novel ROS switcher potentiates the type-I photodynamic effect of sodium zinc chlorophyllin against Pseudomonas aeruginosa in diabetic wounds

Article

作者: Yuan, Cai ; Wang, Guodong ; Chen, Hongjie ; Huang, Mingdong ; Wu, Lusheng

Skin wound infections present a serious threat to human health, with bacterial infections in diabetic wounds being particularly challenging due to impaired healing. Gram-negative bacteria are common pathogens in diabetic wound infections and often exhibit high resistance to conventional treatments, necessitating prolonged and costly therapies. Photodynamic antibacterial therapy (PACT) is regarded as a non-invasive and effective approach, with minimal risk of inducing resistance. Sodium zinc chlorophyllin (ZnChl), a water-soluble metalloporphyrin photosensitizer, offers multiple advantages such as low cost, high safety, and the ability to promote wound healing. However, its bactericidal efficacy against Gram-negative bacteria is limited under the hypoxic conditions typically found in diabetic wounds. Herein, we report a strategy to develop an efficient chlorophyll-based photosensitizer operating via an oxygen-independent Type I mechanism by combining ZnChl with inorganic salts (NaI, KBr, or KI). This approach significantly improved antibacterial performance, particularly with NaI or KI. Upon 630 nm light irradiation, low concentrations of KI (5 mM) markedly enhanced the bactericidal effect of ZnChl (50 μM), reducing the survival of three Gram-negative bacterial strains by 3 logs (99.9%). Interestingly, we further discovered that KI acts as a "reactive oxygen species (ROS) converter," shifting the photodynamic mechanism of ZnChl from a mixed Type I/Type II mode to a dominant Type I mechanism, generating highly reactive hydroxyl radicals (OH). Moreover, the ZnChl-KI combination demonstrated significant therapeutic efficacy in treating Pseudomonas aeruginosa-infected diabetic wounds without inducing apparent toxicity in rats. This work provides a foundation for developing efficient and economical Type I photosensitizers for the treatment of bacterial infections in diabetic wounds.

404

项与诺格白介素α-因奇西普相关的新闻（医药）

2026-07-08

·今日头条

疾病控制率高达100%，全部获益！NK细胞联合疗法打破脑瘤10年僵局

放化疗失效脑胶质瘤全部稳住病灶，5 例患者全部获益！5年生存率仅个位数 GBM 迎来转机，神经肿瘤专家震撼发声：从未见过如此快速缓解！NK 细胞三联疗法改写复发胶质母细胞瘤治疗史！胶质母细胞瘤（GBM）是恶性程度最高的四级脑肿瘤，45 岁以上患者五年生存率仅 6%-9%，绝大多数患者放化疗后快速复发，传统方案几乎无长效手段。ImmunityBio 全球首创全程不用化疗的三联免疫联合方案（ANKTIVA IL-15 激动剂 + PD-L1 t-haNK 细胞 + Optune Gio 肿瘤电场设备），试点研究 5 名全部标准治疗失败的复发胶质母细胞瘤患者交出满分答卷：疾病控制率100%，2人病灶接近完全缓解、2人持续稳定；所有患者放化疗造成的免疫细胞枯竭全部逆转，免疫功能全面回升。该研究（NCT06061809）由霍格家族癌症中心神经肿瘤主任牵头，研究者直言从业多年从未见过如此亮眼的快速缓解效果，攻克胶质母细胞瘤免疫抑制、化疗不耐受两大核心死穴，为复发晚期脑癌开辟无化疗长效免疫新路！疾病控制率高达100%！NK细胞+电场疗法打破脑癌十年僵局！5名患者全部获益本项全球首个无化疗 NK 细胞三联疗法试点研究（NCT06061809）入组人群均为手术、同步放化疗后进展的二线复发胶质母细胞瘤，全部伴随放化疗导致的淋巴细胞减少、免疫系统濒临崩溃，属于临床预后最差的高危人群，临床实验数据非常鼓舞人心： 1、全员病灶100%受控，超半数患者肿瘤明显缩小共计 5 名可评估复发患者，无一人出现肿瘤进展，整体疾病控制率达到 100% ；3 名患者实现客观肿瘤缓解，其中 2 人病灶接近完全消退，剩余 2 人肿瘤长期稳定不增大。对比传统复发 GBM 二线方案，常规治疗客观缓解率不足 10%，本次三联疗法疗效实现断层式领先。 2、逆转放化疗造成的免疫衰竭所有患者经放化疗后均存在严重淋巴细胞偏低、免疫瘫痪；接受 ANKTIVA 联合治疗后，全部受试者外周血淋巴细胞计数显著回升，NK 细胞、杀伤 T 细胞大量增殖，破解胶质母细胞瘤 “免疫冷肿瘤” 难题，解决免疫药无效困境。 3.扩大队列数据持续验证长效生存：23 人入组 19 人存活，免疫崩溃逆转截至 2026 年 1 月数据截止，试验纳入的 23 例复发性胶质母细胞瘤患者（均为放化疗失败、伴严重淋巴细胞减少的 “难治人群”），交出了颠覆历史的答卷：生存期破纪录：疗效可评估的 14 例患者，中位随访 6 个月时，中位 OS 仍 “尚未达到”—— 要知道，这类患者过去的中位 OS 最高只有 9 个月，现在 19 人仍存活，4 例死亡全在可评估人群中，部分患者已活过 12 个月且状态良好；整套方案由 IL-15 超级激动剂 ANKTIVA、PD-L1 改造 NK 细胞、Optune Gio 肿瘤电场三部分协同起效，三重通路同时打击胶质母细胞瘤，解决单一疗法疗效有限的短板： 1、ANKTIVA（IL-15 激动剂）：唤醒全身抗癌免疫军团作为全球首创融合型 IL-15 复合物，无需辅助递呈即可高亲和结合 NK、CD8 杀伤 T 细胞受体，强效促进免疫细胞增殖活化；不激活抑制性 Treg，不会削弱抗肿瘤免疫。既能修复放化疗损伤的免疫系统，提升体内 NK、T 细胞基数，又能生成长效免疫记忆细胞，持续监控颅内微小残留肿瘤，避免短期缓解后快速复发。 2、PD-L1 t-haNK 改造 NK 细胞：精准穿透血脑屏障杀瘤基因改造后的 NK 细胞自带靶向识别结构，可穿透血脑屏障深入颅内肿瘤内部；专门清除表达 PD-L1 的胶质母细胞瘤细胞，打破肿瘤微环境免疫封锁，弥补人体自身 NK 细胞穿透力不足、杀伤能力弱的缺陷。 3、Optune Gio 肿瘤电场设备：阻断癌细胞分裂增殖头皮佩戴便携电场装置，持续释放低强度交变电场，干扰肿瘤细胞有丝分裂，直接抑制 GBM 快速增殖；同时重塑肿瘤局部微环境，让免疫细胞更容易浸润病灶，与 NK 细胞、ANKTIVA 形成 1+1+1＞3 的协同抗癌效果。三者分工配合：电场抑制肿瘤生长、NK 细胞定点清除癌细胞、ANKTIVA 持续维持免疫战斗力，全程不使用任何化疗药物，兼顾疗效与生存质量。从国际上 NK 三联疗法让胶质母细胞瘤患者 “生存期破纪录”，到国内众多NK疗法落地，曾经被判定为 “绝症” 的恶性肿瘤，现在终于有了 “长效生存” 的可能。对于患者来说，现在最该做的不是被 “只剩半年” 的说法吓倒，而是：①尽快做相关检测（PD-L1、ALC）；②整理好病历找专业团队评估，大家可提交病历至全球肿瘤医生医生网医学部评估自身免疫状态。③主动对接新技术 —— 毕竟，2026 年的瘤治疗，早已不是 “听天由命”，而是 “主动出击就能赢”。下一个重新回到正常生活的，可能就是你！

细胞疗法临床研究临床结果免疫疗法

2026-07-08

·allsci.com

UroGen’s UGN-501 oncolytic virus gains FDA clearance for non-muscle invasive bladder cancer trial

UroGen Pharma (Nasdaq: URGN) announced on July 8, 2026 that the US FDA cleared its Investigational New Drug application for UGN-501, an oncolytic virus designed for intravesical delivery in patients with non-muscle invasive bladder cancer (NMIBC). The UGN-501 FDA clearance enables the company to initiate a Phase 1 clinical trial, with patient enrollment expected to begin in Q4 2026. NMIBC is among the most prevalent urological malignancies, and its management is complicated by high recurrence rates even after standard treatment. The disease spans a spectrum of risk — from low-grade papillary tumors to carcinoma in situ (CIS) — and despite an expanding roster of approved therapies, a meaningful proportion of patients continue to experience recurrence or progression. Cystectomy, the definitive surgical option, carries substantial morbidity, and bladder-sparing alternatives remain an active area of development. The approved landscape has expanded considerably in recent years. Merck’s BCG live (Tice BCG) remains the first-line standard of care for intermediate- and high-risk disease following transurethral resection of bladder tumor. For patients whose disease does not respond to BCG, options now include Merck & Co.’s pembrolizumab (Keytruda) administered intravenously, Ferring Pharmaceuticals’ nadofaragene firadenovec-vncg (Adstiladrin) — a non-replicating adenoviral gene therapy delivering interferon-alpha 2b — ImmunityBio’s nogapendekin alfa inbakicept-pmln (Anktiva) combined with BCG, and most recently Janssen Biotech’s gemcitabine intravesical system (Inlexzo), approved in September 2025. UroGen itself received approval in June 2025 for mitomycin intravesical solution (Zusduri), a sustained-release hydrogel formulation targeting recurrent low-grade intermediate-risk NMIBC. Against this backdrop, UGN-501 represents UroGen’s push into a mechanistically distinct space: replication-competent oncolytic virus therapy for bladder cancer, a modality not yet represented among approved NMIBC treatments. UGN-501 (ICVB-1042) is an engineered oncolytic adenovirus that exploits aberrant E2F transcription factor activity — a hallmark of tumor cells — to drive selective viral replication within cancer cells. Normal urothelial tissue, which maintains regulated E2F activity, is designed to be spared. Viral replication within tumor cells leads to direct cell lysis, and the resulting immunogenic cell death is intended to trigger a secondary anti-tumor immune response. This dual mechanism — direct cytotoxicity combined with local immune activation — is the defining rationale for the program. Nonclinical data cited by UroGen demonstrated cytotoxic activity across a broad panel of bladder cancer cell lines representing multiple disease stages and grades, though the company has not publicly disclosed the specific parameters or comparative benchmarks from those studies. The planned Phase 1 clinical trial will assess the safety, tolerability, and feasibility of intravesical UGN-501 administration in NMIBC patients, with no public listing available for the study at present. The oncolytic virus field in bladder cancer has no currently approved representative, making UGN-501 an early mover in this specific modality for NMIBC. Within NMIBC specifically, the closest mechanistic neighbor is nadofaragene firadenovec, which uses a non-replicating adenoviral vector to deliver a therapeutic gene locally. UGN-501 is designed to actively replicate within tumor cells, amplifying its cytotoxic effect in situ, whereas nadofaragene firadenovec functions as a one-time gene delivery vehicle without viral replication. Complete response rates in the BCG-unresponsive CIS setting for currently approved agents range from roughly 40% to 62% at six months, with durability remaining a challenge across the class. An oncolytic approach that generates durable local immune memory, if validated clinically, could offer a meaningful complement or alternative to existing options. UGN-501 is UroGen’s third clinical-stage asset and its first in the oncolytic virus modality. The company’s two approved products — Zusduri and its upper tract urothelial cancer therapy — both rely on the proprietary RTGel reverse-thermal hydrogel platform for sustained local drug delivery. UGN-501 does not use RTGel; it represents a distinct biological approach within the same disease focus. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

临床申请临床1期上市批准基因疗法临床研究

2026-07-06

·国际干细胞与免疫细胞研究

胰腺癌反复进展，有人靠NK联合疗法实现长期完全缓解！

点击蓝字关注我们胰腺癌（PC）是全球第四大癌症相关死亡原因，预后较差。对于接受三线治疗后病情仍持续进展的患者，可选治疗方案寥寥无几，姑息治疗往往成为唯一选择。而《TheOncologist》最新报道的一则案例，为这类难治性患者点亮了希望之光。该案例中的患者为三线治疗后复发的转移性胰腺癌患者，通过同情用药接受N-803、PD-L1t-haNK细胞与EGFR靶向纳米细胞药物偶联物联合治疗后，病情持续稳定超24个月，截至本报告撰写时仍存活。这一突破让我们真切看到胰腺癌治疗的新可能：尽管复发性转移性胰腺癌曾被视为“绝症”，但这位患者的长期生存充分证明，时序性联合治疗方案能突破免疫化疗耐药壁垒、激活抗肿瘤免疫活性，为延长生存期按下“暂停键”。小编坚信，随着免疫联合疗法的持续探索，未来定会有更多难治性胰腺癌患者挣脱命运枷锁，在抗癌之路上迎来更长、更有质量的生命旅程！ ▲截图源自“The Oncologist” NK细胞联合方案让三线治疗无效胰腺癌患者完全缓解，病情稳定超12个月本文案例为一位65岁女性复发性转移性胰腺癌（mPC）患者，5年前确诊局部晚期胰腺癌，具体诊疗如下：患者因腹痛就诊，磁共振胰胆管造影（MRCP）示胰头3.2cm肿块伴胆总管扩张，腹盆部CT提示4.1×3.3cm肿块伴胆管扩张。经3次内镜超声引导下细针穿刺活检（EUS-FNA）提示神经内分泌肿瘤，最终病理确诊为胰腺腺癌，并伴淋巴结肿大。确诊当月行内镜逆行胰胆管造影术（ERCP）并置入胆总管支架，后因胆管炎、胆囊炎接受CT引导下胆囊造瘘管置入术。STRATA基因组测序显示肿瘤为微卫星稳定型（MSS），肿瘤突变负荷（TMB）、PD-L1表达及STRATA免疫特征均偏低，未检出明显基因组改变。患者在确诊后，开启了漫长的治疗：一线治疗：确诊1个月后接受FOLFIRINOX新辅助化疗，期间因胆管炎入院；二线治疗：化疗结束1个月后，行放疗联合卡培他滨同步治疗；三线治疗：3个月后计划行惠普尔手术，但因腹腔镜检出CT/PET未发现的肝转移灶（活检确诊）而被迫中止手术，随即接受吉西他滨联合白蛋白紫杉醇治疗，两个月后PET-CT提示无效。三线无效后，开始接受NK细胞联合治疗：①第一套spIND方案：接受N-803（IL-15免疫激活剂）+PD-L1t-haNK（同种异体PD-L1靶向高亲和力NK细胞）+aldoxorubicin联合治疗，并与吉西他滨+白蛋白紫杉醇进行交替治疗；11个月时加用ETBX-051、ETBX-061疫苗，停用吉西他滨/白蛋白紫杉醇，方案持续2年3个月。因治疗19、24个月时，肝脏出现新病灶伴腹水，最后1个月加做肝脏放疗。②第二套spIND方案：针对病情进展，接受E-EDV-D682（含奈莫霉素）联合EDV-GC治疗。结果显示：治疗第5、8个月CT及PET-CT示病情稳定；治疗14个月时PET-CT未发现异常代谢活性，达到完全缓解（CR）；完成第二套spIND方案后，经影像学检查及胸腔积液检测未发现恶性细胞，证实疾病无进展，该方案已有效控病超12个月。 NK细胞：开启抗癌第一道防线自然杀伤细胞（Natural killer cells，NK细胞）是由造血干细胞分化而来的先天免疫细胞，作为人体第三类淋巴细胞，它不仅能直接杀伤肿瘤细胞，还能通过调节肿瘤微环境发挥抗癌与抗病毒的双重作用，堪称人体对抗癌细胞的“天然斗士”！作为免疫监视的前沿力量，NK细胞在全身血管内持续巡逻，能第一时间识别并锁定体内异常细胞（如癌细胞、感染细胞、衰老细胞等），是公认的抗癌、抗感染“前沿哨兵”。更重要的是，它无需依赖抗原递呈过程，不用“提前通报”就能直接激活，释放颗粒酶、穿孔素等杀伤介质，精准消灭癌细胞，堪称奋战在抗癌一线的“先行军”！既然人体天然存在NK细胞，为何癌症患者还需外源性补充？主要原因有二：一是肿瘤生长可能阻碍NK细胞在骨髓内的正常分化与成熟；二是受癌细胞侵害，体内残存的NK细胞“战斗力”会下降，难以有效识别和消灭癌细胞。因此，通过外源性补充NK细胞，既能增加患者体内NK细胞的数量，又能增强其杀伤活性，进而提升治疗效果。近二十年来，NK细胞疗法凭借这一显著优势，不仅成为白血病等血液肿瘤治疗领域的重要探索方向，目前已有超100项相关临床研究正在推进；在乳腺癌、肝癌、胃癌、结直肠癌、宫颈癌等实体瘤治疗中，其临床结果同样令人振奋，尽显广谱抗癌的强大潜力！相信随着研究不断深入，这道“天然抗癌防线”将为更多患者带来对抗病魔的力量与生命希望，未来值得满心期待！小编寄语 NK细胞（即自然杀伤细胞）是公认的人体抗癌、抗病毒感染的第一道防线。时至今日，研究人员已针对NK细胞进行了大量研究，并肯定了其在支持整个免疫系统中的关键作用，确定了其与多种人类疾病的关联，尤其是尝试将NK细胞用作癌症的治疗。全球肿瘤医生网小编也希望通过这篇文章能让更多癌友，了解并认识到NK细胞这一新型抗癌疗法，为大家带来新的曙光与选择！对现有治疗方案不满意，或想寻求NK细胞疗法、古巴肺癌疫苗、CEA CAR-T、TIL疗法等抗癌新技术帮助的患者，可将近期病理检查报告、治疗经历、出院小结等，提交至国际干细胞与免疫细胞研究医学部，进行初步评估。参考资料 [1]Moini K,et al. Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate[J]. The Oncologist, 2025, 30(3): oyae267. https://academic.oup.com/oncolo/article/30/3/oyae267/7814737 本文为“国际干细胞与免疫细胞研究”原创，转载需授权干细胞与免疫细胞研究入群免费领取抗癌细胞资讯｜新技术｜新药研发｜权威专家资料求分享求收藏求点击求在看

100 项与诺格白介素α-因奇西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12888	-	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性非小细胞肺癌	沙特阿拉伯	ImmunityBio, Inc.	2026-04-21
原位癌	欧盟	ImmunityBio, Inc.	2026-02-16
原位癌	冰岛	ImmunityBio, Inc.	2026-02-16
原位癌	列支敦士登	ImmunityBio, Inc.	2026-02-16
原位癌	挪威	ImmunityBio, Inc.	2026-02-16
非肌层浸润性膀胱尿路上皮癌	沙特阿拉伯	ImmunityBio, Inc.	2026-01-14
淋巴细胞减少	美国	ImmunityBio, Inc.	2025-06-02
非肌层浸润性膀胱肿瘤	美国	Altor BioScience Corp.	2024-04-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
社区获得性肺炎	临床3期	-	ImmunityBio, Inc.	2026-04-15
急性呼吸窘迫综合征	临床3期	-	ImmunityBio, Inc.	2026-04-15
脓毒症	临床3期	-	ImmunityBio, Inc.	2026-04-15
脓毒性休克	临床3期	-	ImmunityBio, Inc.	2026-04-15
肺癌	临床3期	美国	ImmunityBio, Inc.	2022-07-27
晚期非小细胞肺癌	临床3期	美国	ImmunityBio, Inc.	2018-05-18
膀胱癌	临床3期	美国	ImmunityBio, Inc.	2017-06-02
HPV阳性的口咽鳞状细胞癌	临床2期	-	ImmunityBio, Inc.	2026-07-22
HPV16阳性口咽癌	临床2期	-	ImmunityBio, Inc.	2026-07-22
复发性胶质母细胞瘤	临床2期	-	ImmunityBio, Inc.	2026-07-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02782546 (CTgov)	临床2期	急性髓性白血病 \| 难治性急性髓细胞白血病	60	G-CSF+ALT-803+Tacrolimus+mycophenolate mofetil+CIML NK cell infusion (Recipient)	糧壓夢糧範遞鹽壓鬱夢 = 製鹹糧觸醖醖網顧範壓窪製願觸範醖壓淵繭廠 (顧構艱構繭憲鑰願鬱糧, 積醖觸鹽觸構膚廠餘繭 ~ 鹽壓網範顧醖廠壓積艱) 更多	-	2026-06-01
				Leukapheresis (Donor)	窪選遞繭顧衊鏇憲鏇觸(糧憲膚齋簾獵製鹹鹹選) = 製構蓋淵醖醖觸艱願艱製壓遞鬱窪範積淵鑰觸 (艱膚鏇鏇範鹽餘繭願積, 襯積廠膚築鹹簾糧願醖 ~ 鬱遞遞衊膚醖餘淵鑰齋) 更多
NCT03520686 (QUILT-2.023, ASCO2026)	临床3期	非小细胞肺癌一线 PD-L1 TPS	98	CPI+NAI	淵觸繭醖廠鏇餘積鹽鹹(獵蓋鏇鑰襯獵壓範壓網) = 衊願簾廠鏇觸壓鹽膚築蓋積齋餘構淵壓鹹糧憲 (窪簾範鑰觸鏇糧範鏇壓 ) 更多	积极	2026-05-29
				CPI	淵觸繭醖廠鏇餘積鹽鹹(獵蓋鏇鑰襯獵壓範壓網) = 獵選觸壓夢鏇壓築廠衊蓋積齋餘構淵壓鹹糧憲 (窪簾範鑰觸鏇糧範鏇壓 ) 更多
NCT03022825 (QUILT-3.032, ASCO2026)	临床3期	非肌层浸润性膀胱肿瘤	173	nogapendekin alfa inbakicept-pmln + BCG (NAI+BCG)	選糧繭醖齋選餘鬱鏇餘(夢網餘夢製簾積鹽製築) = 夢壓簾膚鬱蓋鑰窪蓋觸膚遞繭顧窪網膚鬱積蓋 (範製願範遞構觸顧鏇憲 ) 更多	积极	2026-05-29
				pembrolizumab (PEMBRO)	選糧繭醖齋選餘鬱鏇餘(夢網餘夢製簾積鹽製築) = 範鬱醖膚網膚糧繭壓廠膚遞繭顧窪網膚鬱積蓋 (範製願範遞構觸顧鏇憲 ) 更多
NCT05419011 (TRIAD5-Plus, Pubmed \| Front Immunol)	临床2期	遗传性非息肉病性结直肠癌 Lynch syndrome	158	Tri-Ad5	窪窪築顧艱餘製憲遞顧(鹹遞構選淵餘夢夢選鏇) = 選製醖夢淵齋糧鏇顧淵鏇鹹糧蓋膚齋夢製構獵 (鏇鹽遞築艱鏇構簾膚廠 )	积极	2026-05-19
				Tri-Ad5 + NAI	窪窪築顧艱餘製憲遞顧(鹹遞構選淵餘夢夢選鏇) = 艱積鏇鑰廠膚選襯窪艱鏇鹹糧蓋膚齋夢製構獵 (鏇鹽遞築艱鏇構簾膚廠 )
NCT06745908 (ResQ201A, ESMO_ELCC2026)	临床3期	-	462	NAI+tislelizumab+docetaxel	範壓艱鬱願鹹觸選壓網(構糧窪糧醖鬱廠範繭憲) = 獵構膚觸築餘壓淵範鹹鑰範鏇簾構製鹹餘製餘 (廠餘積憲選築簾醖簾餘 ) 更多	积极	2026-03-25
				docetaxel	範壓艱鬱願鹹觸選壓網(構糧窪糧醖鬱廠範繭憲) = 願鹽願繭觸齋齋鑰製蓋鑰範鏇簾構製鹹餘製餘 (廠餘積憲選築簾醖簾餘 ) 更多
NCT02523469 (CTgov)	临床1/2期	转移性非小细胞肺癌	67	ALT-803+Nivolumab (Cohort 1: ALT-803 6 µg/kg + Nivolumab 3 mg/kg)	鏇糧觸夢鏇簾構廠齋選 = 構齋憲繭積齋築窪淵積鬱淵築製觸窪繭築廠遞 (壓蓋窪夢築築積蓋醖鬱, 夢構遞齋蓋願鹹衊憲夢 ~ 觸鹹鹹鬱顧衊壓觸醖選) 更多	-	2026-02-17
				ALT-803+Nivolumab (Cohort 2: ALT-803 10 µg/kg + Nivolumab 3 mg/kg)	鏇糧觸夢鏇簾構廠齋選 = 願獵齋壓蓋遞構鹽廠簾鬱淵築製觸窪繭築廠遞 (壓蓋窪夢築築積蓋醖鬱, 壓廠鏇網衊繭選製繭艱 ~ 壓繭範鏇鹽餘獵壓廠鹽) 更多
NCT04491955 (Pubmed \| Oncologist)	临床1/2期	转移性结直肠癌 pMMR	32	CV-301 + N-803 + bintrafusp alfa + PDS01ADC	觸獵願鹽齋鏇選醖選獵(衊構夢鏇觸製製構蓋鹹) = 構築衊衊鏇淵網簾網觸顧築廠網願獵膚憲廠製 (範築選憲夢淵顧壓構繭 ) 更多	不佳	2026-02-05
NCT03228667 (QUILT-3.055, Company_Website) 人工标引	临床2期	非小细胞肺癌二线	-	ANKTIVA + CPI (NSCLC)	廠製襯襯鹹獵餘網蓋繭(願窪範製鏇窪襯繭顧選) = 淵齋遞選鑰觸觸鹹壓蓋構願顧積窪艱觸鏇鑰膚 (鏇鹽餘窪衊醖糧選獵製 )	积极	2026-01-13
				ANKTIVA + CPI (NSCLC + Responders)	製顧鑰構憲齋鬱鏇鏇鏇(觸衊選廠襯鬱襯廠積顧) = 廠鏇鹹夢顧膚蓋簾膚繭窪醖醖艱糧範夢廠繭糧 (築艱鹽構醖鏇繭鏇鏇襯 )
NCT03520686 (QUILT-2.023, Company_Website) 人工标引	临床3期	转移性非小细胞肺癌 \| 晚期非小细胞肺癌一线	-	ANKTIVA + CPI	網選範築壓衊鑰鹽選繭(獵窪鹹醖選鹹淵構鑰壓): P-Value = 0.0065	积极	2026-01-13
				CPI
NCT03022825 (QUILT-3.032, Pubmed \| J Urol)	临床2期	-	54	NAI plus BCG (BCG-unresponsive high-grade Ta/T1 papillary nonmuscle-invasive bladder cancer)	廠壓積衊糧觸衊願顧醖(齋膚網觸鬱簾範鑰淵壓) = 齋醖夢鹹憲鏇艱衊窪網遞壓簾願繭醖構衊膚遞 (獵選簾淵積觸襯構鏇夢, 46.6 ~ 68.2) 更多	积极	2026-01-01